Long-Duration Neoadjuvant FOLFIRINOX Therapy for Pancreatic Cancer Surgery
Study shows similar survival outcomes in pancreatic cancer patients who undergo surgery after long-duration neoadjuvant FOLFIRINOX therapy, regardless of pretreatment resectability status. The majority received FOLFIRINOX alone without radiation, achieving a 76% R0 resection rate. Median overall survival was 41 months and did not vary by disease stage. This research underscores the potential for favorable surgical outcomes with this unique treatment approach.
Removing the rectal tumor and liver spread in one operation did not clearly raise complications or hurt survival compared with two separate operations, a French national study found.
